



The Only FDA-Approved Prescription Combination Drug-Device for Associated Pain, Wound Healing and Vasculitis

Astero®, manufactured by Gensco Pharma, is the only FDA approved prescription combination drug-device indicated for pain. Astero® contains 4% Lidocaine in a hydrogel that provides the relief of pain associated with Closed Skin, Non-Penetrating and Open Wounds, as well as, a treatment for wound healing and vasculitis.

It is indicated for associated pain, painful wounds and wound healing in both Open and Closed injuries or conditions. Conditions of pain include topical pain, postsurgical pain and pain associated with various types of Closed or Open wounds. Conditions of Closed Wounds include soft tissue and bony injuries caused by contusions, hematomas, crush injuries and sprains/strains due to torsion, traction, compression, tearing and/or blunt trauma.

It also is indicated as a healing medium for open wounds caused by trauma, and acute or chronic etiologies including lacerations, surgical wounds, and puncture wounds, severe to mild abrasions and up to second degree burns as well as wounds due to mixed vascular etiologies, diabetic ulcers, arterial and venous stasis ulcers, decubitus ulcers and pressure wounds.

All Gensco products, including Astero®, are distributed to pharmacy chains such as Walgreens®, CVS®, Walmart®, RiteAid®, Kroger® and Publix® through the major wholesalers such as McKesson, Cardinal and AmerisourceBergen. Astero® is contracted with DAPA (Contract #SP0200-15-H-0003), Federal Supply Schedule (FSS), making it accessible to all military personnel and is also available to all MEDICARE patients (Medicare Contract #P1466).



FDA Approved #K092086 | By prescription only

Indications

- Closed wound/non-penetrating
 - Soft tissue injuries and bony contusions secondary to contusions, hematomas, crush injuries, and sprains/strains due to torsion, traction, compression and tearing
 - Trauma
 - Acute and Chronic wounds of various etiologies
 - Associated topical pain
 - Post-surgical incisions
- Open wound for pain and healing
 - Acute and chronic ulcerations
 - Chronic mixed vascular etiologies
 - Diabetic ulcers
 - Arterial and venous stasis ulcers
 - Decubitus ulcers
 - Pressure wounds
- Vasculitis
- First and second degree burns
- Severe to mild cuts and abrasions, lacerations and puncture wounds

asterogel.com

GENSCO PHARMA | 855 743-6726 (7GENSCO)



ED-AS-03 | Mar2017

Astero® Product Information

Product Overview

The unique formulation in Astero® is designed for associated pain, painful wounds and wound healing in both Open and Closed injuries or conditions. Astero® contains a proprietary hydrogel and the familiar topical anesthetic Lidocaine in a 4% concentration. In comparison to patch applications, Astero® is a gel offering an easier application to even difficult areas including joints, non-smooth areas like bony projections and between fingers or toes in patient specific amounts. Astero®, unlike opioids, does not impair patients and therefore does not negatively affect the ability to safely function or return to work. The principles of wound pain management apply to any painful wound. The appropriate use of analgesics and anesthetics is key.¹ Separate pain management strategies may be required for background pain and the pain arising from wound procedures. Both approaches should include local pain control, such as lidocaine, to reduce the need for more aggressive and potentially problematic medications such as NSAIDs and opioids.²

Astero® has a rapid onset of action in 3-5 minutes and is supplied as a Metered Dose (MDose™) pump in an airless 30mL (120 Doses) container that delivers an accurate dose of 0.25 mL per pump.

Clinical Pharmacology

Mechanism of Action

Astero® applied to intact skin or open wounds provides for analgesia by the release of lidocaine from the gel into the epidermal and dermal layers of the skin and by the accumulation of lidocaine in the vicinity of dermal pain receptors and nerve endings.

Indications

Indicated for the relief of painful wounds and wound healing such as:

- Closed wound/non-penetrating
 - Soft tissue injuries and bony contusions secondary to contusions, hematomas, crush injuries, and sprains/strains due to torsion, traction, compression and tearing
 - Trauma
 - Acute wounds and chronic wounds of various etiologies
 - Associated topical pain
 - Post-surgical incisions
- Open wound for pain and healing
 - Acute and chronic ulcerations
 - Chronic mixed vascular etiologies
 - Diabetic ulcers
 - Arterial and venous stasis ulcers
 - Decubitus ulcers
 - Pressure wounds
- Vasculitis
- First and second degree burns
- Severe to mild cuts and abrasions, lacerations and puncture wounds

Use on Intact Skin/Closed Wounds/Non Penetrating Wounds

Astero®, a medicated hydrogel containing 4% Lidocaine, provides topical anesthesia to intact skin and underlying tissues.

Closed wounds have damage that occurs without exposing the underlying tissue and organs (non-penetrating wounds). This includes common conditions such as soft tissue and bony injuries like sprains, strains and contusions due to tearing, traction, compression, torsion, contusions. Also peripheral neuropathies have been shown to benefit from topical lidocaine application.³

Since Astero® is a hydrogel, it offers the ability to be applied to difficult sites and joints in patient specific amounts. The onset, depth and duration of dermal analgesia on intact skin provided by Astero® depends primarily on the duration of application. Also, Astero® provides dermal analgesia by the release of lidocaine from the Hydrogel into the epidermal and dermal layers of the skin and by the accumulation of lidocaine in the vicinity of dermal pain receptors and nerve endings. Since Lidocaine is an amide-type local anesthetic agent it stabilizes neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.

Non-penetrating wounds: These are usually the result of blunt trauma or friction with other surfaces; the wound does not break through the skin, and may include:

- Soft tissue injuries such as muscle strains, tearing, traction, compression, torsion, contusions, and peripheral neuropathies
- Abrasions (scraping of the outer skin layer)
- Lacerations (a tear-like wound)
- Contusions (swollen bruises due to accumulation of blood and dead cells under skin)

There is evidence from an open-label, nonrandomized trial that lidocaine patches were safe and effective for subacute and chronic low back pain when used daily for 6 weeks.⁴ Lidocaine patches are, however, limited in use for several anatomically challenging sites such as knees, elbows, fingers, feet, neck, shoulders, and forearms.

Acute Wound Pain

Astero® is indicated for the treatment of acute wound such as post-surgical wounds, mild to severe abrasions, first and second degree burns, lacerations, and partial thickness avulsions.

There are principally two types of acute wounds: traumatic wounds and surgical wounds. Regardless of etiology of the wound, the correct intervention can greatly affect the outcome for the patient: the scar, time to heal and quality of life. With any acute wound the post-operative function of the wounded area and adequate pain control is essential. If pain is not controlled adequately it can decrease oxygen uptake, increase mortality and morbidity, delay mobility and increase hospital length of stay.

Chronic Wound Pain

Astero® is indicated for chronic wounds such as pressure

wounds, diabetic ulcers, arterial and venous stasis ulcers, decubitus ulcers, vasculitis and ulcers of mixed etiologies, and generally slow healing wounds.

Patients and clinicians both identify wound dressing changes as the most common source of pain.^{1,5} The pain is the result of trauma to the wound bed and peri-wound tissues that is commonly seen with typical adhesive or gauze dressings.^{3,6,7}

Astero® vs Opioids

The treatment of pain with opiate-based medications has increased dramatically over the last decade. In a recent industry report by Helios it was noted that over 60% of workman compensation (WC) patients were treated with opioids, accounting for 33.8% of all WC prescriptions and 30.8% of drug spend. As a consequence, most treatment guidelines for acute injuries at the state and industry level recommend physicians should explore non-opioid medications and other modalities that can be used to reduce the need for opioid medication use.⁸ In a recent case study, lidocaine 4% was used topically for pain control in place of opioids during wound dressing changes.⁹ The lidocaine provided sufficient anesthesia of the wound without any of the unwanted effects of the opiates. The authors found this treatment superior to the standard use of opiate medications in wound pain management.⁸

Summary of Product Research

Numerous studies have demonstrated that hydrogels promote wound debridement by rehydration of non-viable tissue, thus facilitating the process of natural autolysis and improving wound healing rates.^{9,10} The inclusion of lidocaine with the hydrogel provides better wound pain control during dressing changes and debridement. In a recent case study, lidocaine 4% was used topically for pain control in place of opioids during wound dressing changes.¹¹ The lidocaine provided sufficient anesthesia of the wound without any of the unwanted effects of the opiates. The authors found this treatment superior to the standard use of opiate medications in wound pain management. In a recent case study, lidocaine 4% was used topically for pain control in place of opioids during wound dressing changes.¹¹


Product Summary

Astero® has a rapid onset of action (3-5 minutes) and is indicated for associated pain, painful wounds and wound healing in both Open and Closed injuries or conditions. Conditions of pain include topical pain, postsurgical pain and pain associated with various types of Closed or Open wounds. Conditions of Closed Wounds include soft tissue and bony injuries caused by contusions, hematomas, crush injuries and sprains/strains due to torsion, traction, compression and/or blunt trauma.

It also is indicated as a healing medium for open wounds caused by trauma, and acute or chronic etiologies including lacerations, surgical wounds, and puncture wounds, severe to mild abrasions and up to second degree burns as well as wounds due to mixed vascular etiologies, diabetic ulcers, arterial and venous stasis ulcers, decubitus ulcers and pressure wounds.

References

- 1 MEP Ltd; London: 2004. "Minimizing pain at wound dressing-related procedures. A consensus document." World Union of Wound Healing Societies' Initiative
- 2 Cunningham, Michelle MD. Managing Pain Medication in the Outpatient Wound Clinic. Today's Wound Clinic, Volume 7 Issue 4 - May 2013
- 3 Darkovich SL., Brown-Etris M., and Spencer M.: Biofilm hydrogel dressing: a clinical evaluation in the treatment of pressure sores. Ostomy Wound Manage 1990; 29:47
- 4 Kaya AZ., Turani N., and Akyuz M.: The effectiveness of a hydrogel dressing compared with standard management of pressure ulcers. J Wound Care 2005; 14:42
- 5 Moffatt C., Franks P., Hollingworth H. Medical Education Partnership Ltd; London: 2004. "Understanding wound pain and trauma: An international perspective." EWMA position document. 2-7
- 6 Moffatt C., Franks P., Hollingworth H. Medical Education Partnership Ltd; London: 2004. "Pain at wound dressing changes; a guide to management": EWMA position document. 12-17
- 7 Woo K. "Minimising wound-related pain at dressing change: Evidence-informed practice" Ostomy/Wound Management. 2005;51(11A(suppl)):5-6
- 8 Helios Workmans Compensation Drug Trends Report 2015Cunningham, Michelle MD. Managing Pain Medication in the Outpatient Wound Clinic. Today's Wound Clinic, Volume 7 Issue 4 - May 2013
- 9 Okan D., Woo K., and Ayello EA.: The role of moisture balance in wound healing. Adv Skin Wound Care 2007; 20:39 4
- 10 Attinger CE., Janis JE., Steinberg J., Schwartz J., Al-Attar A., and Couch K.: Clinical approach to wounds: debridement and wound bed preparation including the use of dressings and wound healing adjuvants. Plast Reconstr Surg 2006; 117(7S):72
- 11 Agrawal, Vaidehi; Wilson, Kirby; Reyna, Roxana; Emran, Mohammad Ali. Feasibility of 4% Topical Lidocaine for Pain Management During Negative Pressure Wound Therapy Dressing Changes in Pediatric Patients: A Case Study. Journal of Wound, Ostomy & Continence Nursing: November/December 2015 - Volume 42 - Issue 6 - p 640-642 10





30mL: NDC 35781-2500-3

READ THIS INFORMATION BEFORE PRESCRIBING THIS PRODUCT

INDICATIONS AND USAGE

Astero® is a medicated Hydrogel for wounds in a Metered Dose (M-DOSE™) bottle containing Lidocaine Hydrochloride 4%, an amide type local anesthetic. A wound is defined as a tear, rupture, herniation or trauma resulting in the lack of continuity of a tissue of the body either internal or external. An open wound is a break in the skin or in a mucous membrane. A closed wound involves underlying tissues without a break in the skin or a mucous membrane. Astero® is indicated for associated pain, painful wounds and wound healing in either open and closed injuries or conditions. Conditions of pain include topical pain, postsurgical pain and pain associated with various types of closed or open wounds. Conditions of closed wounds include soft tissue and bony injuries caused by contusions, hematomas, crush injuries and sprains/strains due to torsion, traction, compression, tearing and/or blunt trauma. It also is indicated as a healing medium for open wounds caused by trauma, and acute or chronic etiologies including lacerations, surgical wounds, and puncture wounds, severe to mild abrasions and up to 2nd degree burns as well as wounds due to mixed vascular etiologies, diabetic ulcers, arterial and venous stasis ulcers, decubitus ulcers and pressure wounds.

DOSEAGE

Apply to the affected area as directed. Maximum 12 pumps per day.

DOSEAGE FORMS AND STRENGTHS

Astero® is a topical medicated hydrogel for wounds. Each gram of Astero® contains 4% Lidocaine HCl USP (40mg).

CONTRAINDICATIONS

Lidocaine Hydrochloride USP is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

WARNINGS AND PRECAUTIONS

For External Use Only. Avoid Contact with Eyes. If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. Astero® should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of Lidocaine Hydrochloride USP.

ADVERSE REACTIONS

Most common adverse reactions are redness or swelling at the application site. Less common side effects, such as sluggishness, confusion, slow breathing, low blood pressure, or slow heartbeat, may occur. To report SUSPECTED ADVERSE REACTIONS, contact Gensco Pharma at 866-608-6284 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Prilocaine, Bupivacaine, Amyl nitrate/sodium nitrate/sodium thiosulfate, Dofetilide, Lomitapide, Beta-blockers (e.g., atenolol), Cimetidine, or Class I antiarrhythmic drugs (ex. Mexiletine). This may not be a complete list of all interactions that may occur. Ask your health care provider if Astero® may interact with other medicines that you take.

USE IN SPECIFIC POPULATIONS

Use in Pregnancy: Teratogenic Effects - Pregnancy Category B. Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lidocaine Hydrochloride USP is administered to a nursing woman. Pediatric use: Dosage in children should be reduced, commensurate with age, body weight and physical condition. Geriatric use: No overall clinical differences in safety or effectiveness have been observed between the healthy elderly and other adult patients.

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING | 1 INDICATIONS AND USAGE | 2 DOSEAGE AND ADMINISTRATION 2.1 Dosage for children 2.2 Administration | 3 DOSEAGE FORMS AND STRENGTHS | 4 CONTRAINDICATIONS | 5 WARNINGS AND PRECAUTIONS | 6 ADVERSE REACTIONS 6.1 Central nervous system 6.2 Cardiovascular system 6.3 Allergic | 7 DRUG INTERACTIONS 7.1 Serious interactions 7.2 General interactions | 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Labor and Delivery 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use | 9 OVER DOSAGE 9.1 Management of local anesthetic emergencies | 10 DESCRIPTION 10.0 Active Ingredients 10.2 Inactive Ingredients | 11 CLINICAL PHARMACOLOGY 11.1 Mechanism of Action 11.2 Onset of Anesthesia 11.3 Hemodynamics 11.4 Pharmacokinetics and Metabolism | 12 NONCLINICAL TOXICOLOGY 12.1 Carcinogenesis, Mutagenesis, Impairment of Fertility | 13 HOW SUPPLIED / STORAGE AND HANDLING

* Sections or subsections omitted from the prescribing information are not listed.

Warning: FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. EXCESSIVE DOSEAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS OF LIDOCAINE AND SERIOUS ADVERSE EFFECTS. PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSEAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT. THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS.

1. **Indications:** Astero® is indicated for associated pain, painful wounds and wound healing in either open and closed injuries or conditions. Conditions of pain include topical pain, postsurgical pain and pain associated w/ various types of closed or open wounds. Conditions of closed wounds include soft tissue and bony injuries caused by contusions, hematomas, crush injuries and sprains/strains due to torsion, traction, compression and/or blunt trauma. It also is indicated as a healing medium for open wounds caused by trauma, and acute or chronic etiologies including lacerations, surgical wounds, and puncture wounds, severe to mild abrasions and up to 2nd degree burns as well as wounds due to mixed vascular etiologies, diabetic ulcers, arterial and venous stasis ulcers, decubitus ulcers and pressure wounds.

2. **Dosage and Administration:** Each pump of the Astero® bottle (30mL Airless Metered Dose bottle) (NDC:35781-2500-3) will deliver 0.25 mL of Astero® (10 mg Lidocaine Hydrochloride USP), enough to cover a 2-inch by 2-inch area of skin. A single application should not exceed 4 pumps of the M-DOSE bottle, equal to 1 gram of Astero®, (40 mg of Lidocaine Hydrochloride USP).

No more than 12 pumps of the M-DOSE bottle, approximately 3 grams of Astero® (120 mg Lidocaine Hydrochloride USP.) should be administered in any one day. Although the incidence of adverse effects with Astero® is quite low, caution should be exercised, particularly when employing large amounts, since the incidence of adverse effects is directly proportional to the total dose of local anesthetic agent administered.

2.1 **Dosage for children:** The recommended dose of Astero® varies as a function of age and weight. For children less than ten years who have a normal lean body mass and a normal lean body development, the maximum dose may be determined by the application of one of the standard pediatric drug formulas (e.g., Clark's rule). For example, a child of five years weighing 50 lbs., the dose of lidocaine should not exceed 75-100 mg (approximately 1.9 to 2.5 grams of Astero®) when calculated according to Clark's rule. In general, the maximum amount of lidocaine administered should not exceed 4.5 mg/kg (2.0 mg/lb) of body weight of the child. Do not use on children under 2 unless directed by a physician.

2.2 **Administration:** Apply as directed. Do not exceed 12 pumps in a twenty-four-hour (24-hour) period. One pump covers an area of 2 x2 inches.

3. **Dosage Form and Strength:** Astero® is a topical medicated hydrogel wound dressing. Each gram of Astero® contains 4% Lidocaine Hydrochloride USP (40mg).

4. **Contraindications:** Lidocaine Hydrochloride USP is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of Astero®.

5. **Warnings and Precautions:** If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. Astero® should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of Lidocaine Hydrochloride USP. In case of accidental ingestion get medical help or contact Poison Control Center right away.

6. **Adverse Reactions:** Adverse experiences following the administration of Lidocaine Hydrochloride USP are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:

6.1 **Central nervous system:** CNS manifestations of Lidocaine toxicity are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of Lidocaine Hydrochloride USP is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.

6.2 **Cardiovascular system:** Cardiovascular manifestations of Lidocaine toxicity are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest.

6.3 **Allergic:** Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to the local anesthetic agent or to other components in the formulation. Allergic reactions as a result of sensitivity to Lidocaine Hydrochloride USP are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.

7. Drug Interactions:

7.1 **Serious interactions:** Antiarrhythmic Drugs: Astero® should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Bupivacaine liposome: Lidocaine Hydrochloride USP increases toxicity of Bupivacaine by increasing the free (unencapsulated) bupivacaine. Dofetilide: Lidocaine Hydrochloride USP increases effects of dofetilide through pharmacodynamic synergism. Lomitapide: Lidocaine Hydrochloride USP increases levels of lomitapide by affecting hepatic/intestinal enzymes CYP3A4 metabolism.

7.2 **General interactions:** Drugs metabolized via CYP3A4 enzyme: (ex. Antipsychotics, SSRIs, TCAs, many chemotherapeutics, calcium channel blockers, benzodiazepines) Lidocaine Hydrochloride USP may increase serum levels of many drugs metabolized by hepatic / intestinal CYP3A4 enzymes. Drugs that affect hepatic CYP1A2 enzyme: (ex. Quinolone antibiotics, cimetidine, barbiturates, benzodiazepines, erythromycin) May increase serum Lidocaine Hydrochloride USP levels by decreasing Lidocaine Hydrochloride USP metabolism by CYP1A2 enzyme.

8. Use in Specific Populations:

8.1 **Use in Pregnancy:** Teratogenic Effects of Lidocaine Hydrochloride USP. Pregnancy Category B. Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by Lidocaine Hydrochloride USP. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering Lidocaine Hydrochloride USP to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.

8.2 **Labor and Delivery:** Lidocaine Hydrochloride USP is not contraindicated in labor and delivery. Should Astero® be used concomitantly with other products containing Lidocaine Hydrochloride USP, the total dose contributed by all formulations must be kept in mind.

8.3 **Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lidocaine Hydrochloride USP is administered to a nursing woman.

8.4 **Pediatric use:** Dosage in children should be reduced, commensurate with age, body weight and physical condition. Caution must be taken to avoid over dosage when applying Astero® to large areas of injured or abraded skin, since the systemic absorption of Lidocaine Hydrochloride USP may be increased under such conditions. Do not use on children under 2 unless directed by a physician.


8.5 **Geriatric use:** No overall clinical differences in safety or effectiveness have been observed between the healthy elderly and other adult patients.

9. **Over Dosage:** Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics. (see ADVERSE REACTIONS, WARNINGS, and PRECAUTIONS).—

9.1 **Management of local anesthetic emergencies:** The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anesthetic administration. At the first sign of change, oxygen should be administered. The first step in the management of convulsions consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously. Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine). If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted. Dialysis is of negligible value in the treatment of acute over dosage with Lidocaine Hydrochloride USP. The oral LD50 of Lidocaine HCl USP in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats.

10. Description:

10.1 **Active Ingredients:** Each gram of Astero® contains Lidocaine Hydrochloride USP 4% (40 mg). Lidocaine Hydrochloride USP is chemically designated as acetamide, 2- (diethylamino)-N-(2,6-dimethylphenyl), and has the following structure:



10.2 **Inactive Ingredients:** Polyethylene Glycol(PEG) 400 & Polyethylene Glycol 3350 as base, Oak Extract, Meadowsweet Extract, Zinc Acetate, and Water.

11. Clinical Pharmacology:

11.1 **Mechanism of action:** Astero®, when applied to wounds, provides for analgesia by the release of lidocaine from the gel into the epidermal and dermal layers of the skin and by the accumulation of lidocaine in the vicinity of dermal pain receptors and nerve endings. Astero® is a hydrated polymer (Hydrell) wound dressing containing 4% w/w Lidocaine HCl USP. By providing moisture to the wound, Astero® creates a moist healing environment, which promotes granulation, epithelialization, and autolytic debridement. The high water content of hydrogel dressings cools the wound, producing pain relief that can last up to 6 hours. Dressing-change discomfort is also reduced because Astero® doesn't adhere to the wound surface.

Astero® releases Lidocaine Hydrochloride USP from the Neutral (pH 7-7.2) hydrogel to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action.

11.2 **Onset of anesthesia:** Astero® effects local, topical anesthesia. The onset of action is 3-5 minutes.

11.3 **Hemodynamics:** Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. These changes may be attributable to a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system.

11.4 **Pharmacokinetics and metabolism:** Lidocaine Hydrochloride USP may be absorbed following topical administration to mucous membranes or open wounds, its rate and extent of absorption depending upon the specific site of application, duration of exposure, concentration, and total dosage. Lidocaine Hydrochloride USP is also well-absorbed from the gastrointestinal tract, but little intact drug appears in the circulation because of biotransformation in the liver. Lidocaine Hydrochloride USP is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinyxylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of Lidocaine Hydrochloride USP. Approximately 90% of Lidocaine Hydrochloride USP administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. The plasma binding of Lidocaine Hydrochloride USP is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 µg of free base per mL, 60 to 80 percent of Lidocaine Hydrochloride USP is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein. Lidocaine Hydrochloride USP crosses the blood-brain and placental barriers, presumably by passive diffusion. Studies of Lidocaine Hydrochloride USP metabolism following intravenous bolus injections have shown that the elimination half-life of this agent is typically 1.5 to 2.0 hours. Because of the rapid rate at which Lidocaine Hydrochloride USP is metabolized, any condition that affects liver function may alter Lidocaine Hydrochloride USP kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect Lidocaine Hydrochloride USP kinetics but may increase the accumulation of metabolites.

Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of Lidocaine Hydrochloride USP required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6.0 µg free base per mL. In the rhesus monkey arterial blood levels of 18-21 µg/mL have been shown to be threshold for convulsive activity.

11.5 **Pharmacodynamics:** The penetration of lidocaine into intact skin and open wounds after application is sufficient to produce an analgesic effect, but less than the amount necessary to produce a complete sensory block.

12. **Non-Clinical Toxicity:** Studies of Lidocaine Hydrochloride USP in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted.

13. How Supplied / Storage and Handling:

HOW SUPPLIED: Astero® (Medicated Hydrogel containing Lidocaine HCl USP 4%) | 1.0oz (28.5g) 30mL Airless Pump - NDC 35781-2500-3

STORE AND DISPOSE OF THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN AND PETS. All prescriptions using this product shall be pursuant to state statutes as applicable. This product may be administered only under a physician's supervision. There are no implied or explicit claims on the therapeutic equivalence. Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86° F). See USP Controlled Room Temperature. Protect from freezing.

Manufactured for: Gensco Laboratories, 8550 NW 33rd Street, Suite 200, Doral, FL 33122